• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

SARS-like WIV1-CoV poised for human emergence - 2016, work based on a 2002 patent

Emily

Editor, Senior Moderator
https://rumble.com/v2dtlru-covid-vi...university-chapel-hill-david-martin-upda.html
2 days ago
Covid Virus Made In North Carolina University Chapel Hill: David Martin Update 3-17-23
This is a Kim Iverson Show interview with patent expert Dr. David Martin. Dr. David Martin Ph.D. founder of M·CAM® and has published across various fields in law, medicine, engineering, finance, and education. He recently appeared in Mikki Willis’ documentary Plandemic. There is ample documented proof the Covid 19 Virus was made at the University of North Carolina Chapel Hill with U.S. tax dollars. Was China involved? Yes totally...
 
UNC epidemiology study: New SARS-like virus may be nearly ready to infect humans

EPIDEMIOLOGY NEWS, EPIDEMIOLOGY RESEARCH, GLOBAL NEWS, RESEARCH NEWS
March 15, 2016

A study led by researchers at the University of North Carolina at Chapel Hill found that a SARS-like virus known as WIV1-CoV, which is found in horseshoe bats, could bind to the same receptors as SARS-CoV and replicate in human cells without the need for adaptation. Thought to be a critical barrier, the results indicate that bat populations maintain SARS-like viruses poised to reemerge in humans.

The study, titled “SARS-like WIV1-CoV poised for human emergence,” was published in the latest issue of the Proceedings of the National Academy of Science (PNAS). The study’s primary investigator is Ralph Baric, PhD, professor of epidemiology at UNC’s Gillings School of Global Public Health.

“This study goes beyond sequence analysis, which clearly has its limits,” Baric said. “We focused on SARS-like coronaviruses isolated from Chinese horseshoe bats, where SARS originated. One that we identified, WIV1-CoV, was a very likely candidate for transmission to humans.”


The research team worked with both full length and chimeric versions of WIV1-CoV. The virus readily and efficiently replicated in cultured human airway tissues, suggesting an ability to potentially jump directly to humans.

The research team also found that monoclonal antibodies developed to treat SARS were effective in both human and animal tissue samples against WIV1-CoV. However, existing vaccines against SARS would not provide protection for this new virus.

SARS (Severe Acute Respiratory Syndrome) was first seen in an outbreak in 2002 and resulted in 8,000 cases and nearly 800 deaths. Spread through airborne contact, its onset presents symptoms similar to the flu with a dry cough but can accelerate rapidly to pneumonia, filling the lungs with fluid and putting extreme stress on the body’s immune system. According to the Centers for Disease Control and Prevention (CDC), SARS’ mortality rate can range from less than one percent in patients below age 24 years to more than 50 percent in patients aged 60 years and older. The researchers involved with the UNC-led study theorized that WIV1-CoV has the potential to induce similar results with proper adaptation to humans.


“There is a subset of coronaviruses currently circulating in bats that have the ability to bind and enter human cells,” said Vineet Menachery, PhD, a postdoctoral fellow in the Baric Lab at UNC Gillings who is also the study’s first author. “Instead of being the result of a rare mutation, the capacity of this group of viruses to jump into humans is greater than we originally thought.”

While other adaptations may be required to produce an epidemic, several viral strains circulating in bat populations have already overcome the barrier of replication in human cells and suggest reemergence as a distinct possibility.

Baric and Menachery say that other researchers can build on their findings with additional viral families and that studies with full length and chimeric versions of SARS-like viruses are the key to developing better therapeutics, including both vaccine and antibody approaches.

“This type of work generates information about novel viruses circulating in animal populations and develops resources to help define the threat these pathogens may pose to human populations,” Baric said. “It’s important to note that it’s not an approach that’s limited to SARS or SARS-like viruses. It can be applied to other emerging pathogens to helping us prepare for the next emergent virus, whether it be MERS, the Zika virus or something we haven’t even heard of yet.”


https://sph.unc.edu/sph-news/unc-epi...infect-humans/

-------------------------------------------------------------------------------------------------------

from the paper:


Acknowledgments

We thank Dr. Zhengli-Li Shi of the Wuhan Institute of Virology for access to bat CoV sequences and plasmid of WIV1-CoV spike protein. Research was supported by the National Institute of Allergy and Infectious Disease and the National Institute of Aging of the NIH under Awards U19AI109761 and U19AI107810 (to R.S.B.), AI1085524 (to W.A.M.), and F32AI102561 and K99AG049092 (to V.D.M.). Human airway epithelial cell cultures were supported by the National Institute of Diabetes and Digestive and Kidney Disease under Award NIH DK065988 (to S.H.R.). Support for the generation of the mice expressing human ACE2 was provided by NIH Grants AI076159 and AI079521 (to A.C.S.).

https://www.pnas.org/doi/full/10.1073/pnas.1517719113
 
I think it is not accurate to blame efforts from over 20 years ago for today's pandemic. Did a long chain of gain-of-function efforts end up contributing 20 years later to a pandemic? Possibly, but the blame lies squarely in the years immediately before the pandemic. What exactly were the experiments in the 2015 - 2019 time range? What labs and researchers were doing this? What was going on with lab biosecurity at each lab? What animals were being used? Any dogs?
 
I agree that China has a massive problem which I have posted about in past years. The male to female imbalance is a big deal. I do not agree that there has been a global conspiracy to wipe out the population by maximizing profits for the drug industry. Reason this: If big pharma conspires with global elites to kill millions or billions of people then who is left to buy more drugs? i.e. Does it make any sense to bite the hand that is feeding you? Doesn't it make more sense to keep those who survive infancy around for decades to be able to develop many different products to sell them throughout their life cycle?

If it is a crime for big pharma to maximize profits then how is that any different for anyone who makes a lotta $ from anti-pharma sites, products, podcasts, books, etc.? Seems the same parasitic behavior to me. Selling is selling. Plain and simple.

This all still gets back to you. Read. A lot. View multiple information sources. Talk to medical practitioners that you trust. Ask questions. Get 2nd and 3rd opinions. Use your common sense.

Take care of you.
 
Sharon, I don't remember a 2002 patent mentioned in the interview. (OK, it was late. I found a print copy of his position. https://www.davidmartin.world/wp-content/uploads/2021/12/The-Criminal-Conspiracy-of-Coronavirus.pdf Both Sars 1 and 2 raise questions for him.)

I think this experiment was done, or at least completed, in 2015. Dr. Martin does not believe any pharma companies are trying to wipe out huge populations. You are right that companies want to keep market share. Pfizer is moving into cancer and autoimmune drugs now.
I know for a fact that some companies make decisions on a cost basis even regarding causing serious harm such as blindness or death, based on the tradeoff of lawsuits vs the cost of fixing something vs profits. (Government fines are chump change.) There is no lawsuit factor in EUA drugs unless maybe extreme malfeasance can be proven. (I don't know the law that well.) That is why I would never take a drug product unless there is liability.
Dr. Martin isn't selling any government mandated products as being safe and effective, so there is no potential moral equivalence even if he's selling anything. I didn't pay anything to watch the interview, but my taxes were paid for free pandemic shots that people were forced to take to eat and have shelter in many cases.
 
I don't think you need an intermediate for any of these.

https://journals.asm.org/doi/full/10.1128/JVI.02582-15
Spotlight Selection
26 February 2016

Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus


ABSTRACT

We report the isolation and characterization of a novel bat coronavirus which is much closer to the severe acute respiratory syndrome coronavirus (SARS-CoV) in genomic sequence than others previously reported, particularly in its S gene. Cell entry and susceptibility studies indicated that this virus can use ACE2 as a receptor and infect animal and human cell lines. Our results provide further evidence of the bat origin of the SARS-CoV and highlight the likelihood of future bat coronavirus emergence in humans.
...


We recently isolated a bat SL-CoV strain (WIV1) and constructed an infectious clone of another strain (SHC014); significantly, these strains are closely related to SARS-CoV and capable of using the same cellular receptor (angiotensin-converting enzyme 2 [ACE2]) as SARS-CoV (6, 7). Despite the high similarity in genomic sequences and receptor usage of these two strains, there is still some difference between the N-terminal domains of the S proteins of SARS-CoV and other SL-CoVs, indicating that other unknown SL-CoVs are circulating in bats.

Here we report the isolation of a new SL-CoV strain, named bat SL-CoV WIV16. SL-CoV WIV16 was isolated from a single fecal sample of Rhinolophus sinicus, which was collected in Kunming, Yunnan Province, in July 2013.
...
The overall nucleotide sequence of WIV16 has 96% identity (higher than that of any previously reported bat SL-CoVs) to human and civet SARS-CoVs (Table 1) (46, 813). A detailed comparison of protein sequences between SARS-CoV GZ02, a strain from an early-phase patient, and all reported bat SL-CoVs indicated that WIV16 is the closet progenitor of the SARS-CoV in most proteins, particularly in the S protein (Table 1).
...

The WIV16 S gene has 95% sequence identity at the nucleotide level and 97% identity at the amino acid level to SARS-CoVs, much higher than those of WIV1, which has 88% identity at the nucleotide level and 90% identity at the amino acid level.
 
Back
Top Bottom